DDInter120 DDInter1376
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Arsenic trioxide {u} (Compound) binds {v} (Gene) JUN
Arsenic trioxide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Arsenic trioxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Arsenic trioxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Arsenic trioxide {u} may lead to a major life threatening interaction when taken with {v} Perphenazine
Arsenic trioxide {u} may lead to a major life threatening interaction when taken with {v} Histrelin
Arsenic trioxide (Compound) binds JUN (Gene)
Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Arsenic trioxide may lead to a major life threatening interaction when taken with Perphenazine
Arsenic trioxide may lead to a major life threatening interaction when taken with Histrelin